SCHEMBL6411459

SCHEMBL6411459

O=C(O)C1=NOC2(CCN(C(=O)COc3cccc(Cl)c3)CC2)C1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.58
ENPP2 Q13822 7/20 0.54
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
GAA P10253 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
GLA P06280 3/20 0.42
HPGD P15428 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402439 0.86 ALDH1A1 (0.52) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL6411463 0.86 FKBP1A (0.56) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL2399304 0.83 FKBP1A (0.48) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL2399331 0.81 FKBP1A (0.61) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL6410978 0.80 FKBP1A (0.48) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL2400070 0.79 PKM (0.49) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL2399298 0.77 RAB9A (0.56) MAPTKMT2AMEN1KDM4EALDH1A1
SCHEMBL6413986 0.76 FKBP1A (0.46) FKBP1AENPP2MAPTKMT2AMEN1
SCHEMBL2404903 0.76 GRM5 (0.52) ALDH1A1
SCHEMBL15837602 0.75 MEN1 (0.56) KMT2AMEN1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP claimed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US claimed
US-8557796-B2 Substituted 1-oxa-2,8-diaza-spiro [4,5] dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2013-10-15 US disclosed
EP-1401841-B1 SUBSTITUTED 1-OXA-2,8-DIAZA-SPIRO 4,5]DEC-2-ENE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2005-08-24 EP disclosed
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods GRUENENTHAL GMBH (DE) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192916-A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives and related treatment methods SULT1E1, CYP4B1, CYP3A4 FKBP1A 2995/4885ENPP2 3123/4885MAPT 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.